Phase 3 N=480 A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Change in Knee Pain — -0.91; -0.89 score on a scale — p=0.94
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Medical Management of Sleep Disturbance During Opioid Tapering
Opioid Dependence · Opioid Withdrawal · Sleep Disturbance
Primary: Abuse Liability as Assessed by Visual Analogue Scale — 23.9; 20.9; 22.8 score on a scale*days — p=.950
Phase 3 N=32 Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents
HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Less Than 50 Copies Per Milliliter (c/mL) at Week 48 — 81…
N/A N=53 Immediate Weight Bearing Versus Protected Weight Bearing in Supracondylar Distal Femur Fractures
Closed Supracondylar Fracture of Femur
Primary: Time to Distal Femur Fracture Healing by Radiographic Evidence — 1.75; 2.15 months
N/A N=166 Electrical Stimulation for the Treatment of Back Pain Using Peripheral Nerve Stimulation (PNS)
Back Pain · Low Back Pain
Primary: Number of Subjects That Experienced ≥30% Reduction in Average Low Back Pain Intensity — 58 Participants
N/A N=11 A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients
End Stage Renal Disease (ESRD)
Primary: Clearance and Solute Removal Characteristics of Dialyzers — 354.1; 340.4; 361.8; 271.8 milliliters per minute (ml/min) — p=<0.001
Phase 2 N=84 Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
Leukemia · Myelodysplastic Syndrome · Lymphoma
Primary: Percent of Engrafted Participants With Successful Neutrophil Recovery — 96 % w/incidence of neutrophil recovery
Phase 4 N=5 Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9
Phase 2 N=422 HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Acute Lymphoblastic Leukemia · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: The Incidence of Durable Hematopoietic Engraftment for T-cell Depleted Transplants Fractionated by the CliniMACS System Administered After Each of the Four Disease…
Phase 1 N=25 Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Dose-limiting Toxicities (DLT) Rate — 0; 0; 1; 0 Participants
Phase 2 N=60 Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
Hepatocellular Carcinoma
Primary: Overall Response Rate — 6; 30; 17; 0 Participants
N/A N=81 Tragus Stimulation to Prevent Atrial Fibrillation After Cardiac Surgery
Atrial Fibrillation
Primary: Time to the First Episode of Atrial Fibrillation (AF) >30 Seconds — 53.1; 52.2 hours — p=0.60
Phase 2 N=26 A Study of Definitive Therapy to Treat Prostate Cancer
Prostate Cancer
Primary: Efficacy as Assessed by 2-year PSA Progression-free Survival Rate — 17 Participants
Phase 2 N=110 A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
NASH - Nonalcoholic Steatohepatitis
Primary: Main: Absolute Change From Baseline in Hepatic Fat Fraction Assessed by MRI-PDFF at Week 12. — -12.32; -13.44; -14.14; -0.29 Absolute percentage of hepatic fat
Phase 2 N=98 Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs) — 0; 1; 1; 0 Participants